Exciting times in CLL: an ASCO 2013 interview ... - CLL Support

CLL Support

22,513 members38,667 posts

Exciting times in CLL: an ASCO 2013 interview with Dr Susan O’Brien

AussieNeil profile image
AussieNeilAdministrator
1 Reply

In this 18 minute video interview, Dr Susan O’Brien of MD Anderson, discusses some of the CLL data presented at ASCO 2013 and shares her perspective on several of the exciting new targeted agents in development, including some good news for those of us with co-morbidities.

pharmastrategyblog.com/2013...

Neil (with thanks from a fellow Aussie John from our sunshine state, for drawing my attention to this video)

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
1 Reply
Kwenda profile image
Kwenda

As I have posted before, if Dr Susan O'Brien talks, it is time to listen.

Apart from being tremendously impressed with her range of knowledge, this video clearly shows the advances made in formulating a treatment for CLL. There are very good reasons to be optimistic that a simple pill will one day be able to put CLL into remission.

Scroll down on the video page and there is a link to tumur lysis syndrome that I posted about earlier.

Dick

You may also like...

Exciting times in CLL: an ASCO 2013 interview with Dr Susan O’Brien

http://pharmastrategyblog.com/2013/06/asco-2013-cll-interview-susan-obrien.html/

ASCO 2016: Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib in CLL

posted an interview from ASCO 2016 with Dr. Susan O’Brien where she discusses frontline data on...

ASH 2013: INTERVIEW WITH DR. FURMAN RE: IDELALISIB

blogspot.com ), I have a short and interesting video interview with Dr. Furman who was the lead on...

ASCO 2014: Dr. Susan O'Brien Reviews the 3 years follow-up Data on Ibrutinib in CLL

http://bkoffman.blogspot.com some of the 3 year trial data on single agent ibrutinib in the...

CLL Society Dr. Koffman's ASCO 2020 \"Top 12\" Picks #s 12, 11, 10

Oncology (ASCO) was held virtually in May. While ASCO remains more focused on the latest research...